Freedom of Information request (FOI 22/1158)
Published 17 January 2024
漏 Crown copyright 2024
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at /government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-26-december-2022/freedom-of-information-request-foi-221158
30th December 2022
FOI 22/1158
Dear
Thank you for your FOI request dated 1st December 2022.
We can confirm that data relating to the number of prescriptions of 鈥渃annabis-based product for medicinal use in humans鈥� (CBPMs) is not held by the MHRA.
The MHRA does hold information regarding adverse reactions to CBPMs and this can be accessed using the link below:
The substance Cannabidiol should cover all the licensed CBPMs on the market as well as unlicensed products and food supplements. Additionally Cannabis Sativa is the plant which would contain some multi-constituent CBD products including Hemp which you may also be interested in looking at.
Please see the link below to one company led recall, this information is publicly available on the 188体育 page: /drug-device-alerts/company-led-medicines-recall-noidecs-t20-slash-c4-thc-20-percent-cbd-4-percent-indica-cannabis-flower-unlicensed-medicine-and-noidecs-t20-slash-c4-thc-20-percent-cbd-4-percent-sativa-cannabis-flower-unlicensed-medicine
We can confirm that no other recalls have taken place.
We hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.
Kind regards,
FOI Team